Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence.
COVID-19
adverse events
cancer
immune modulation
immune suppression
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
03
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19. Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig. 89 studies were included. Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19. No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFα blockade is harmful to patients in the context of COVID-19. COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19. Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19. The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients. Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα agents are contraindicated. There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.
METHODS
METHODS
Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig.
RESULTS
RESULTS
89 studies were included. Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19. No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFα blockade is harmful to patients in the context of COVID-19. COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19. Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19.
CONCLUSION
CONCLUSIONS
The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients. Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα agents are contraindicated. There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.
Identifiants
pubmed: 32256705
doi: 10.3332/ecancer.2020.1022
pii: can-14-1022
pmc: PMC7105343
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1022Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Front Microbiol. 2018 Dec 12;9:3097
pubmed: 30619176
Antiviral Res. 2006 Aug;71(1):53-63
pubmed: 16621037
Antivir Chem Chemother. 2007;18(1):1-11
pubmed: 17354647
J Neurovirol. 2017 Dec;23(6):845-854
pubmed: 28895072
Clin Microbiol Rev. 2015 Apr;28(2):465-522
pubmed: 25810418
Antivir Chem Chemother. 2009;19(4):151-6
pubmed: 19374142
J Med Virol. 2005 Feb;75(2):185-94
pubmed: 15602737
Biochem Biophys Res Commun. 2005 Mar 25;328(4):979-86
pubmed: 15707974
Antiviral Res. 2010 Nov;88(2):160-8
pubmed: 20727913
Microbiol Immunol. 2009 Feb;53(2):75-82
pubmed: 19291090
Bioorg Med Chem. 2003 Oct 15;11(21):4599-613
pubmed: 14527557
Int J Mol Med. 2005 Feb;15(2):323-7
pubmed: 15647850
Curr Med Chem. 2005;12(18):2095-162
pubmed: 16101496
Chest. 1999 Mar;115(3):901-5
pubmed: 10084516
Virol Sin. 2020 Mar 3;:
pubmed: 32125642
Curr Opin Pharmacol. 2012 Aug;12(4):464-70
pubmed: 22819198
J Med Virol. 2020 Mar 17;:
pubmed: 32181911
J Pediatr (Rio J). 2014 Jul-Aug;90(4):370-6
pubmed: 24703819
Respir Investig. 2020 Feb 21;:
pubmed: 32094077
J Infect Dis. 2015 Dec 15;212(12):1904-13
pubmed: 26198719
Virology. 2007 Dec 20;369(2):288-98
pubmed: 17804032
Antivir Ther. 2006;11(8):1021-30
pubmed: 17302372
Zhonghua Nei Ke Za Zhi. 2005 Dec;44(12):890-3
pubmed: 16409721
Virus Res. 2014 May 12;184:44-53
pubmed: 24566223
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Front Microbiol. 2019 Jan 29;10:50
pubmed: 30761102
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208
pubmed: 32164089
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
Pediatrics. 2004 Jan;113(1 Pt 1):e7-14
pubmed: 14702488
Infect Immun. 2004 Aug;72(8):4410-5
pubmed: 15271897
J Med Virol. 2006 Apr;78(4):417-24
pubmed: 16482545
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 06;43(0):E005
pubmed: 32026671
J Korean Med Sci. 2016 Nov;31(11):1717-1725
pubmed: 27709848
J Immunol. 2005 Jun 15;174(12):7977-85
pubmed: 15944304
Virus Res. 2012 Apr;165(1):112-7
pubmed: 22349148
Zhonghua Zhong Liu Za Zhi. 2020 Mar 05;42(0):E008
pubmed: 32133833
Cell Mol Immunol. 2004 Jun;1(3):193-8
pubmed: 16219167
Virology. 2009 Dec 20;395(2):210-22
pubmed: 19853271
Expert Rev Anti Infect Ther. 2005 Apr;3(2):251-62
pubmed: 15918782
Clin Biochem Rev. 2004 May;25(2):121-32
pubmed: 18458712
J Antimicrob Chemother. 2008 Sep;62(3):437-41
pubmed: 18565970
Vopr Onkol. 2006;52(4):421-6
pubmed: 17024815
Antimicrob Agents Chemother. 2014 Aug;58(8):4251-2
pubmed: 24867994
J Virol. 2009 Apr;83(7):3039-48
pubmed: 19004938
J Gen Virol. 2014 Mar;95(Pt 3):571-577
pubmed: 24323636
J Biol Regul Homeost Agents. 2019 Feb 4;34(1):
pubmed: 32013309
Virology. 2011 Nov 25;420(2):106-16
pubmed: 21959016
J Med Microbiol. 2003 Aug;52(Pt 8):715-720
pubmed: 12867568
J Virol. 2019 May 29;93(12):
pubmed: 30918074
J Virol. 2018 Oct 29;92(22):
pubmed: 30185587
Zhonghua Jie He He Hu Xi Za Zhi. 2003 Oct;26(10):586-9
pubmed: 14633438
Vet Immunol Immunopathol. 2010 Sep 15;137(1-2):12-9
pubmed: 20466438
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Feb 26;23(0):E004
pubmed: 32100980
J Antimicrob Chemother. 2016 Dec;71(12):3340-3350
pubmed: 27585965
Annu Rep Med Chem. 2007 Feb 1;41:183-196
pubmed: 19649165
J Infect. 2013 Dec;67(6):606-16
pubmed: 24096239
BMC Infect Dis. 2016 Apr 21;16:174
pubmed: 27097824
Antiviral Res. 2015 Mar;115:9-16
pubmed: 25542975
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Virology. 2007 Sep 1;365(2):324-35
pubmed: 17490702
Lancet. 2003 Jun 14;361(9374):2045-6
pubmed: 12814717
Vet Pathol. 1983 Nov;20(6):653-61
pubmed: 6649336
J Virol. 2008 May;82(9):4420-8
pubmed: 18287230
Infect Dis (Lond). 2020 Feb 18;:1-4
pubmed: 32067542
Blood. 2010 Mar 11;115(10):2088-94
pubmed: 20042728
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
J Med Microbiol. 2017 Sep;66(9):1261-1274
pubmed: 28855003
J Virol. 2007 Nov;81(21):11620-33
pubmed: 17715225
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275
pubmed: 27937060
PLoS One. 2016 Jun 16;11(6):e0157398
pubmed: 27309354
Curr Med Res Opin. 2004 Jan;20(1):39-40
pubmed: 14741070
J Med Chem. 2016 Jul 28;59(14):6595-628
pubmed: 26878082
Clin Infect Dis. 2017 Jun 1;64(11):1532-1539
pubmed: 28329354
Clin Infect Dis. 2004 Oct 1;39(7):1071-5
pubmed: 15472864
Antiviral Res. 2018 Feb;150:155-163
pubmed: 29289665
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Microbes Infect. 2013 Feb;15(2):88-95
pubmed: 23123977
Am J Transplant. 2015 Apr;15(4):1101-4
pubmed: 25716741
Cytokine. 2019 Mar;115:13-23
pubmed: 30616034
Sci Rep. 2017 Jun 22;7(1):4105
pubmed: 28642467
J Formos Med Assoc. 2005 Oct;104(10):715-23
pubmed: 16385373
J Pediatr Hematol Oncol. 2019 May;41(4):e242-e246
pubmed: 30688827
Future Virol. 2011 May;6(5):615-631
pubmed: 21765859
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):
pubmed: 32171193